Differential effect of cannabis use on opioid agonist treatment outcomes: Exploratory analyses from the OPTIMA study

• DOI: 10.1016/j.josat.2023.209031
• Publication Date: 2023-03-30T23:29:32Z
• Authors: Laurent Elkrief; Gabriel Bastien; Christina McAnulty; Hamzah Bakouni; François-Olivier ...; M. Eugenia Socias; Bernard Le Foll; Ron Lim; Omar Ledjiar; Stéphanie Marsan; Suzanne Brissette; Didier Jutras-Aswad; Susan Bornemisza; Helen Bouman; Sarah Elliott; Laura Evans; Monty Ghosh; Lucas Gursky; Lydia Vezina; Cam Wild; Alvis Yu; Keith Ahamad; Paxton Bach; Rupinder Brar; Nadia Fairbairn; Christopher Fairg...; Sonia Habibian; Sukhpreet Klaire; Scott MacDonald; Mark McLean; Seonaid Christine...; Gerrit Prinsloo; Christy Sutherland; Evan Wood; Nikki Bozinoff; Benedikt Fischer; Mike Franklin; Ahmed Hassan; Dafna Kahana; Dina Lagzdins; David Marsh; Jürgen Rehm; David Barbeau; Julie Bruneau; Sidney Maynard; Annie Talbot; Louis-Christophe ...
• Keywords: Analgesics, Opioid; Narcotic Antagonists; Opiate Substitution Treatment; Humans; Bayes Theorem; Buprenorphine, Naloxone Drug Combination; Opioid-Related Disorders; Methadone; 3. Good health; Cannabis; Buprenorphine; Substance Withdrawal Syndrome

Conflictual evidence exists regarding the effects of cannabis use on outcomes opioid agonist therapy (OAT). In this exploratory analysis, we examined effect recent use, craving, and withdrawal symptoms, in individuals participating a trial comparing flexible buprenorphine/naloxone (BUP/NX) take-home dosing model to witnessed ingestion methadone. We analyzed data from multi-centric, pragmatic, 24-week, open label, randomized controlled with prescription-type disorder (n = 272), randomly assigned BUP/NX 138) or methadone 134). The study measured last week via timeline-follow back, recorded at baseline every two weeks during study. Craving symptoms were using Brief Substance Scale baseline, 2, 6, 10, 14, 18 22. Clinical Opiate Withdrawal treatment initiation 4, 6. mean maximum dose taken was 17.3 mg/day (range 0.5–32 mg/day) for group 67.7 10–170 group. Repeated measures generalized linear mixed models demonstrated that (mean 2.3 days) not significantly associated (aβ ± standard error (SE) −0.06 0.04; p 0.15), craving SE −0.05 0.08, 0.49), 0.09 0.1, 0.36). Bayes factor (BF) each tested supported null hypothesis (BF < 0.3). current did demonstrate statistically significant interest context pragmatic randomized-controlled trial. These findings replicated previous results reporting no opioid-related outcomes.